Company research
Savara Inc
CIK 1160308Updated Sep 27, 2026
SecuritySVRA · NASDAQ · equity
Name history
Mast Therapeutics, Inc. · through Apr 25, 2017ADVENTRX PHARMACEUTICALS INC · through Mar 1, 2013BIOKEYS PHARMACEUTICALS INC · through May 15, 2003
SVRA price & chart
Loading TradingView…
NASDAQ:SVRA on TradingView ↗About the company
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Savara’s lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Savara’s management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
In the news
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA News provided by DJS Law Group LLP Nov 07, 2025, 03:19 ET Share this article Share to X Share this article Share to X LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investor ↗
Recent filings
S-8 filing
10-Q filing
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 253,436,000Source | 212,879,000Source | 177,564,000Source | 139,777,000Source |
| Property, Plant and Equipment, NetUSD | 100,000Source | 165,000Source | 270,000Source | 51,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 33,180,000Source | 15,128,000Source | 26,585,000Source | 52,100,000Source |
| Assets, CurrentUSD | 241,616,000Source | 202,135,000Source | 165,947,000Source | 128,954,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,914,000Source | 5,808,000Source | 3,628,000Source | 3,078,000Source |
| Operating Lease, Right-of-Use AssetUSD | 100,000Source | 200,000Source | 400,000Source | 100,000Source |
| Other Assets, NoncurrentUSD | 84,000Source | 242,000Source | 387,000Source | 116,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 50,303,000Source | 41,430,000Source | 37,192,000Source | 31,999,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 204,000Source | 173,000Source | 140,000Source | 116,000Source |
| Retained Earnings (Accumulated Deficit)USD | -608,087,000Source | -489,250,000Source | -393,369,000Source | -338,671,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -87,000Source | -750,000Source | -271,000Source | -605,000Source |
| Stockholders' Equity Attributable to ParentUSD | 203,133,000Source | 171,449,000Source | 140,372,000Source | 107,778,000Source |
| Additional Paid in Capital, Common StockUSD | 811,103,000Source | 661,276,000Source | 533,872,000Source | 446,938,000Source |
| Liabilities and EquityUSD | 253,436,000Source | 212,879,000Source | 177,564,000Source | 139,777,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 20,396,000Source | 14,724,000Source | 10,597,000Source | 5,867,000Source |
| Operating Lease, Liability, CurrentUSD | — | 200,000Source | 200,000Source | 60,000Source |
| Accounts Payable, CurrentUSD | 5,757,000Source | 4,545,000Source | 3,504,000Source | 1,334,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 100,000Source | 200,000Source | 50,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 87,000Source | 247,000Source | 54,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 14,639,000Source | 10,179,000Source | 7,093,000Source | 4,533,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 29,907,000Source | 26,619,000Source | 26,348,000Source | 26,078,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 29,907,000Source | 26,619,000Source | 26,348,000Source | 26,078,000Source |
| Short-term InvestmentsUSD | 202,522,000Source | 181,199,000Source | 135,734,000Source | 73,776,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,421,000Source | 9,860,000Source | 4,178,000Source | 2,041,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -101,037,000Source | -89,088,000Source | -51,061,000Source | -34,554,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -18,440,000Source | -39,941,000Source | -57,116,000Source | 52,645,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 22,000Source | 25,000Source | 296,000Source | 9,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 137,806,000Source | 117,577,000Source | 82,780,000Source | 87,000Source |
| Repayments of Long-term DebtUSD | 27,229,000Source | — | — | 26,350,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 18,052,000Source | -11,457,000Source | -25,515,000Source | 18,088,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,201,000Source | 2,124,000Source | 2,040,000Source | 1,614,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 14,421,000Source | 9,860,000Source | 4,178,000Source | 2,041,000Source |
| Amortization of Debt Issuance CostsUSD | 453,000Source | 271,000Source | 271,000Source | 334,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 310,000Source | 51,000Source | 76,000Source | -19,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -546,000Source | — | — | — |
| General and Administrative ExpenseUSD | 42,056,000Source | 25,037,000Source | 15,668,000Source | 10,929,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 9,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Operating ExpensesUSD | 123,547,000Source | 103,196,000Source | 60,007,000Source | 38,839,000Source |
| Other Nonoperating Income (Expense)USD | 4,710,000Source | 7,315,000Source | 5,309,000Source | 689,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 29,598,000Source | — | — | 26,438,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 182,200,000Source | 165,000,000Source | 137,400,000Source | 130,793,000Source |
| Proceeds from Stock Options ExercisedUSD | 347,000Source | 347,000Source | 283,000Source | 2,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -123,547,000Source | -103,196,000Source | -60,007,000Source | -38,839,000Source |
| Other Nonoperating Income (Expense)USD | 4,710,000Source | 7,315,000Source | 5,309,000Source | 689,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 9,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Earnings Per Share, BasicUSD per share | -0.53Source | -0.48Source | -0.33Source | -0.25Source |
| Earnings Per Share, DilutedUSD per share | -0.53Source | -0.48Source | -0.33Source | -0.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 222,387,531Source | 198,191,936Source | 165,204,652Source | 152,771,817Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 222,387,531Source | 198,191,936Source | 165,204,652Source | 152,771,817Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 9,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 87,000Source | 130,000Source | 77,000Source | 31,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 310,000Source | 51,000Source | 76,000Source | -19,000Source |
| General and Administrative ExpenseUSD | 42,056,000Source | 25,037,000Source | 15,668,000Source | 10,929,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -84,300,000Source | -63,256,000Source | -40,834,000Source | -29,326,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 4,162,000Source | 6,467,000Source | 4,436,000Source | -88,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Operating ExpensesUSD | 123,547,000Source | 103,196,000Source | 60,007,000Source | 38,839,000Source |
Filing attachments
d24211dex991.htm · 8-K · 2026-01-09
EX-99.1 2 d24211dex991.htm EX-99.1 EX-99.1 Corporate Overview January 2026 Developing new therapies for rare respiratory diseases Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among othe…
Read attachment ↗d62228dex41.htm · 8-K · 2025-10-30
EX-4.1 3 d62228dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: October 31, 2025 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Ho…
Read attachment ↗d62228dex991.htm · 8-K · 2025-10-30
EX-99.1 5 d62228dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pa., October 29, 2025 - Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so ch…
Read attachment ↗d55049dex991.htm · 8-K · 2025-10-29
EX-99.1 2 d55049dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF MOLBREEVI* IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) - RTW Committed $75M in Launch Funding, Subject to U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - - Royalties Based on Annual Net Sales of MOLBREEVI in the U.S. - - Funds Will Strengthen the Company’s Balance Sheet for Potential U.S. Commercialization…
Read attachment ↗d55049dex992.htm · 8-K · 2025-10-29
EX-99.2 3 d55049dex992.htm EX-99.2 EX-99.2 Corporate Overview October 2025 © Savara Inc. All Rights Reserved. Exhibit 99.2 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements …
Read attachment ↗d12513dex991.htm · 8-K · 2025-09-02
EX-99.1 2 d12513dex991.htm EX-99.1 EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases September 2025 © Savara Inc. All Rights Reserved. Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipat…
Read attachment ↗